
Judith Michels

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7008257/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer. , 2022, 10, e004280.		7
2	Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer. Cancer Immunology, Immunotherapy, 2021, 70, 519-531.	2.0	22
3	Pyridoxal kinase and poly(ADP-ribose) affect the immune microenvironment of locally advanced cancers. Oncolmmunology, 2021, 10, 1950954.	2.1	2
4	Metabolic features of cancer cells impact immunosurveillance. , 2021, 9, e002362.		11
5	Metabolic enzymes expressed by cancer cells impact the immune infiltrate. Oncolmmunology, 2019, 8, e1571389.	2.1	15
6	Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial. Oncolmmunology, 2018, 7, e1428157.	2.1	18
7	Metabolic vulnerability of cisplatinâ€resistant cancers. EMBO Journal, 2018, 37, .	3.5	84
8	Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature, 2017, 548, 234-238.	13.7	394
9	Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. European Journal of Cancer, 2016, 69, 151-157.	1.3	31
10	Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. Oncolmmunology, 2016, 5, e1177692.	2.1	52
11	Prime time for immune-checkpoint targeted therapy at ASCO 2015. Oncolmmunology, 2016, 5, e1068494.	2.1	8
12	Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients: Side study of the EORTC 18961 trial Journal of Clinical Oncology, 2016, 34, 3032-3032.	0.8	0
13	Abstract 2256: Establishment and characterization of circulating tumor cell-derived xenografts in non-small cell lung cancer. , 2016, , .		0
14	Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. Annals of Oncology, 2015, 26, 2470-2477.	0.6	20
15	Epithelial ovarian carcinoma in very young patients Journal of Clinical Oncology, 2015, 33, e16546-e16546.	0.8	0
16	Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene, 2014, 33, 3894-3907.	2.6	89
17	Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. Proceedings of the United States of America, 2014, 111, 3020-3025.	3.3	59
18	PARP and other prospective targets for poisoning cancer cell metabolism. Biochemical Pharmacology, 2014, 92, 164-171.	2.0	24

JUDITH MICHELS

#	Article	IF	CITATIONS
19	MCL-1 dependency of cisplatin-resistant cancer cells. Biochemical Pharmacology, 2014, 92, 55-61.	2.0	54
20	Abstract 4691: Overactivation of poly (ADP-ribose) polymerase (PARP) in localised non-small cell lung cancer (NSCLC) predicts dismal prognosis. , 2014, , .		0
21	Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle, 2013, 12, 877-883.	1.3	57
22	Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. Oncogene, 2013, 32, 4995-5004.	2.6	108
23	Prognostic value of LIPC in non-small cell lung carcinoma. Cell Cycle, 2013, 12, 647-654.	1.3	16
24	Cisplatin Resistance Associated with PARP Hyperactivation. Cancer Research, 2013, 73, 2271-2280.	0.4	143
25	Functions of BCL-X _{L} at the Interface between Cell Death and Metabolism. International Journal of Cell Biology, 2013, 2013, 1-10.	1.0	71
26	Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. Cell Cycle, 2013, 12, 417-421.	1.3	26
27	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 257-269.	2.9	122
28	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 1472.	2.9	0
29	Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31, 1869-1883.	2.6	2,058
30	Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e37563.	1.1	252
31	Abstract 3115: PARP overactivation predicts the susceptibility of human cancer cells to apoptosis induction by PARP inhibitors. , 2012, , .		0
32	Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients. Pharmaceutical Research, 2011, 28, 3199-3207.	1.7	36
33	Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Investigational New Drugs, 2010, 28, 690-693.	1.2	22
34	Treatment for metastatic malignant melanoma: Old drugs and new strategies. Critical Reviews in Oncology/Hematology, 2010, 74, 27-39.	2.0	105